ArticleProceedings of the National Academy of Sciences of the United States of America2020
Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.New microbes and new infections · 2026Review
- Revisiting the Status of Yellow Fever Epizootics and Its Surveillance in South America: New Non-Human Primates, Spillover and Ecological Drivers.Pathogens (Basel, Switzerland) · 2026Review
- Yellow Fever in Pregnancy: A Comprehensive Review of the Clinical Implications and Vaccination in the Context of the 2024-2026 Americas Outbreak.Tropical medicine and infectious disease · 2026Review
- Mesenteric Ischemia and Bacterial Translocation Precipitate the Intoxication Phase of Yellow Fever.The Journal of infectious diseases · 2026Article
- Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Pulmonary Complications in Fatal Yellow Fever, Brazil, 2017-2019.Emerging infectious diseases · 2026Article
- Article
- Platforms to Evaluate Flavivirus-Induced Immunoinflammatory Responses and Their Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Review
- Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection.JCI insight · 2025Article
- Colombian consensus on the care of critically ill patients with suspected or confirmed severe yellow fever.Lancet regional health. Americas · 2025Review
- Amino acid changes in two viral proteins drive attenuation of the yellow fever 17D vaccine.Nature microbiology · 2025Article
- Two mutations in NS2B are responsible for attenuation of the yellow fever virus (YFV) vaccine strain 17D.PLoS pathogens · 2025Article
- Yellow Fever in Non-Human Primates: A Veterinary Guide from a One Health Perspective.Veterinary sciences · 2025Review
- Intensive Therapeutic Plasma Exchange-New Approach to Treat and Rescue Patients with Severe Form of Yellow Fever.Tropical medicine and infectious disease · 2025Article
- Mice Engrafted with Human Liver Cells.Seminars in liver disease · 2024Review
- The neonatal Fc receptor (FcRn) is a pan-arterivirus receptor.Nature communications · 2024Article
- Levels of Angiopoietin 2 Are Predictive for Mortality in Patients Infected With Yellow Fever Virus.The Journal of infectious diseases · 2024Article
- Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell reports. Medicine · 2024Article
- Vascular dysfunction in hemorrhagic viral fevers: opportunities for organotypic modeling.Biofabrication · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
Yellow fever (YF) is a mosquito-transmitted viral disease that causes tens of thousands of deaths each year despite the long-standing deployment of an effective vaccine. In its most severe form, YF manifests as a hemorrhagic fever that causes severe damage to visceral organs. Although coagulopathy is a defining feature of severe YF in humans, the mechanism by which it develops remains uncertain. Hepatocytes are a major target of yellow fever virus (YFV) infection, and the coagulopathy in severe YF has long been attributed to massive hepatocyte infection and destruction that results in a defect in clotting factor synthesis. However, when we analyzed blood from Brazilian patients with severe YF, we found high concentrations of plasma D-dimer, a fibrin split product, suggestive of a concurrent consumptive process. To define the relationship between coagulopathy and hepatocellular tropism, we compared infection and disease in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.